健脾益肾颗粒治疗肺癌伴发贫血临床研究
|
摘要
癌症伴发贫血是指恶性肿瘤患者由于肿瘤本身或化疗、放疗等原因所导致的贫血,在肿瘤进展期发生率较高,如晚期肺癌患者贫血发生率可高达50%～60%。贫血不但降低肿瘤患者的生活质量,而且严重影响放化疗效果和预后。目前,输血和应用重组人红细胞生成素是治疗癌症伴发贫血的有效手段,然而疗效维持时间短,所带来的副作用以及高额费用限制了其临床应用。癌症伴发贫血属于中医“血虚”、“虚劳”等范畴,我们认为病机关键缘于脾肾亏虚,故确立健脾益肾、补气生血的治疗原则,并以健脾益肾颗粒为治疗药物,采用前瞻性、随机、平行对照方法,客观地评估了健脾益肾颗粒治疗肺癌伴发贫血的临床疗效。
根据临床研究方案,在北京地区2家三级甲等医院,根据贫血严重程度、TNM分期、既往化疗周期数,按“不平衡指数最小的分配原则”对入选的肺癌伴发贫血患者进行随机化分组。2个疗程结束时,共收集有效病例60例,两组各30例。研究结果表明:①试验组中医症状总评分逐渐降低(P<0.001),显效20例(66.67%),有效8例(26.67%),无效2例(6.67%),有效率93.33%;对照组总评分治疗前后无显著差异(P>0.05),显效6例(20.00%),有效9例(30.00%),无效15例(50.00%),有效率50%。经MANOVA分析,两组中医症状总评分降低均呈曲线趋势,试验组降低较对照组明显(P<0.05);经Wilcoxon非参数检验,试验组中医症状有效率明显优于对照组(P<0.001)。②神疲乏力、食欲减退、食后腹胀、头晕耳鸣、面色无华主要单项症状,试验组治疗后较治疗前明显改善(P<0.05),对照组治疗前后未见明显变化(P>0.05),两组之间有显著差异(P<0.01)。③试验组Hb水平稳定(P>0.05),对照组Hb水平比治疗前明显下降(P<0.05),呈线性降低趋势。经MANOVA分析,Hb变化两组之间无显著性差异(P>0.05)。④两组RDW治疗后均较治疗前明显增高,经MANOVA分析,两组RDW增高均呈曲线趋势,对照组RDW增高较试验组明显(P<0.05)。⑤试验组MCH、MCV逐渐升高(P<0.05,P<0.01),RBC、MCHC、HCT治疗前后无显著差异(P>0.05);对照组MCH治疗后比治疗前明显降低(P<0.05),RBC、MCHC、MCV和HCT治疗前后比较均无显著性差异(P>0.05)。
Cancer-related anemia results from malignant tumor,chemotherapy,radiotherapy and so on.It occurs in high probability,especially for the advanced stage.About 50% to 60% of advanced lung cancer may appear anemia.Not only cancer-related anemia can impair quality of life,but also it can badly influence curative effect and clinical prognosis.Both blood transfusion and recombination human erythropoietin are effective treatments.Nevertheless,their applications are restricted by the short duration,side effects and expensive cost.In traditional chinese medicine(TCM),cancer-related anemia belongs to the categories of“xue xu”(deficiency of blood),“xu lao”(consumptive diseases)and others.Deficiency of spleen ahd kindey is the main causation,according to which,strengthening the spleen,reinforcing the kidney,invigorating qi and nourishing blood is established as therapeutic principle.We accurately assessed the clinical effect of Jianpi Yishen granule in lung cancer patients suffering from cancer-related anemia by prospectively randomized control clinical trial.
At the basis of project,60 cases were admitted in two first-grade,first-class Beijing hospitals from when two periods of treatment were finished.They were divided into two groups on principle of minimizing imbalance index in anemia degree,TNM grade and previous chemotherapy cycles.There were 30 patients in each group.Both groups subjected to necessary treatments including chemotherapy,radiotherapy and heteropathy.Only the treated group subjected to Jianpi Yishen granule.There are results following.
①The grade of clinical symptoms falled gradually in treated group(P<0.001).20 of them showed significant improvement(66.67%),8 of them had response(26.67%)and the rest 2 cases were futile(6.67%).The response rate was 93.33%.At the same time,the control group made no difference after treatment(P>0.05).6 of them improved significantly(20.00%),9 of them had response(30.00%)and 15 cases were futile(50.00%).The response rate was 50%.It was concluded by multivariate analysis of variance(MANOVA)that the downtrend of grade was curve in two groups.Further more,the treated group descended excessively(P<0.05).Analysed by Wilcoxon nonparametric test,the response rate of clinical symptoms in the treated group remarkably excelled the control group(P<0.001).②The main symptoms include lack of vitality,lassitude,loss of appetite,abdominal distention,dizziness,tinnitus and dim complexion.The treated group improved prominently on every single symptom(P<0.05).Whereas,the control group do not have obvious change(P>0.05).There was significant difference between them(P<0.01).③The level of hemoglobin(Hb) keep stable in treated group(P>0.05)when linearly dropping in control group(P<0.05).MANOVA revealed that the change got no statistic significance between them(P>0.05).④Red blood cell volume distribution width(RDW)became larger in two groups.By MANOVA,we knew that
根据临床研究方案,在北京地区2家三级甲等医院,根据贫血严重程度、TNM分期、既往化疗周期数,按“不平衡指数最小的分配原则”对入选的肺癌伴发贫血患者进行随机化分组。2个疗程结束时,共收集有效病例60例,两组各30例。研究结果表明:①试验组中医症状总评分逐渐降低(P<0.001),显效20例(66.67%),有效8例(26.67%),无效2例(6.67%),有效率93.33%;对照组总评分治疗前后无显著差异(P>0.05),显效6例(20.00%),有效9例(30.00%),无效15例(50.00%),有效率50%。经MANOVA分析,两组中医症状总评分降低均呈曲线趋势,试验组降低较对照组明显(P<0.05);经Wilcoxon非参数检验,试验组中医症状有效率明显优于对照组(P<0.001)。②神疲乏力、食欲减退、食后腹胀、头晕耳鸣、面色无华主要单项症状,试验组治疗后较治疗前明显改善(P<0.05),对照组治疗前后未见明显变化(P>0.05),两组之间有显著差异(P<0.01)。③试验组Hb水平稳定(P>0.05),对照组Hb水平比治疗前明显下降(P<0.05),呈线性降低趋势。经MANOVA分析,Hb变化两组之间无显著性差异(P>0.05)。④两组RDW治疗后均较治疗前明显增高,经MANOVA分析,两组RDW增高均呈曲线趋势,对照组RDW增高较试验组明显(P<0.05)。⑤试验组MCH、MCV逐渐升高(P<0.05,P<0.01),RBC、MCHC、HCT治疗前后无显著差异(P>0.05);对照组MCH治疗后比治疗前明显降低(P<0.05),RBC、MCHC、MCV和HCT治疗前后比较均无显著性差异(P>0.05)。
Cancer-related anemia results from malignant tumor,chemotherapy,radiotherapy and so on.It occurs in high probability,especially for the advanced stage.About 50% to 60% of advanced lung cancer may appear anemia.Not only cancer-related anemia can impair quality of life,but also it can badly influence curative effect and clinical prognosis.Both blood transfusion and recombination human erythropoietin are effective treatments.Nevertheless,their applications are restricted by the short duration,side effects and expensive cost.In traditional chinese medicine(TCM),cancer-related anemia belongs to the categories of“xue xu”(deficiency of blood),“xu lao”(consumptive diseases)and others.Deficiency of spleen ahd kindey is the main causation,according to which,strengthening the spleen,reinforcing the kidney,invigorating qi and nourishing blood is established as therapeutic principle.We accurately assessed the clinical effect of Jianpi Yishen granule in lung cancer patients suffering from cancer-related anemia by prospectively randomized control clinical trial.
At the basis of project,60 cases were admitted in two first-grade,first-class Beijing hospitals from when two periods of treatment were finished.They were divided into two groups on principle of minimizing imbalance index in anemia degree,TNM grade and previous chemotherapy cycles.There were 30 patients in each group.Both groups subjected to necessary treatments including chemotherapy,radiotherapy and heteropathy.Only the treated group subjected to Jianpi Yishen granule.There are results following.
①The grade of clinical symptoms falled gradually in treated group(P<0.001).20 of them showed significant improvement(66.67%),8 of them had response(26.67%)and the rest 2 cases were futile(6.67%).The response rate was 93.33%.At the same time,the control group made no difference after treatment(P>0.05).6 of them improved significantly(20.00%),9 of them had response(30.00%)and 15 cases were futile(50.00%).The response rate was 50%.It was concluded by multivariate analysis of variance(MANOVA)that the downtrend of grade was curve in two groups.Further more,the treated group descended excessively(P<0.05).Analysed by Wilcoxon nonparametric test,the response rate of clinical symptoms in the treated group remarkably excelled the control group(P<0.001).②The main symptoms include lack of vitality,lassitude,loss of appetite,abdominal distention,dizziness,tinnitus and dim complexion.The treated group improved prominently on every single symptom(P<0.05).Whereas,the control group do not have obvious change(P>0.05).There was significant difference between them(P<0.01).③The level of hemoglobin(Hb) keep stable in treated group(P>0.05)when linearly dropping in control group(P<0.05).MANOVA revealed that the change got no statistic significance between them(P>0.05).④Red blood cell volume distribution width(RDW)became larger in two groups.By MANOVA,we knew that
引文
1 Ludwig H,Fritz E.Anemia in cancer patients.Senin oncol,1998,25(supple 7):2～6
2 Jerome EG,Loretta MI.Chemotherapy-Induced Anemia in Adults.Incidence and Treatment.J Natl Cancer Inst,1999,91:1616～1634
3 Skiuings JR,Rogers-Melamed I,Nabholtz JM,et al.An epidemiological review of anemia in cancer chemotherapy in Cannada,proceedings of the European Conference on clinicaloncology and Cancer Nursing European Society of Therapeutic Radiology and Oncology.Paris France,October 29～November 2,1995:183
4 宋国红,刘淑俊,聂均,等.肿瘤伴发贫血及其对肿瘤患者生活质量影响的调查.肿瘤防治杂志,2003,10(11):1186～1188
5 Reed WR,Hussey DH,De Gowin RL.Implications of the anemia of chronic disorders in patients anticipating radiotherapy.Am J Med sci,1994,308:9～15
6 Okamoto H,Saijo N,Shinkai T,et al.Chemotherapy-induced anemia in patients with primary lung cancer.Ann oncol,1992,3:819～824
7 Wozniak AJ,Crowley JJ,Balcerxak SP,et al.Randomized trail comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced NSCLC:a southwest Oncology Group study.J clin oncol,1998,16:2459～2465
8 Elis PA,Smith IE,Hardy JR,et al.Symptom relief with MVP(mitomycin c,vinblastine and cisplatin)chemotherapy in advanced NSCLC.Br J Cancer,1995,71:366～370
9 Post mus PE,Giaccone G,Debruyne C,et al.Results of the phase ⅠEORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with NSCLC.EORTC lung cancer cooperating group,Semin Oncol,1996,23(supple 12):10～13
10 Hainsworth JD,Levitan N,Wampler GL,et al.phase Ⅰ randomized study of cisplatin plus etoposide phosphate or etoposidein the treatment of small-cell lung cancer(SCLC).J clin oncol,1995,13:1436～1442
11 Loehter PJ SR,Ansari R,Gonin R,et al.Cisplatin plus etoposide with and without ifosfamide in extensive SCLC a Hoosier oncology groop study.J clin oncol,1995,13:1594～1599
12 Miuer AA,Hermdon JE znd,Houis DR,et al.Schedule dependency of 21-day oral versus 3-day intravenous etopside in combinatoion with intravenous cisplatin in extensiveSCLC:a randomized phase Ⅰ study of the cancer of leukemia group B.J clin oncol,1995,13:1871～1879
13 韩瑞刚,彭瑞云.电离辐射对骨髓损伤的研究进展.中华放射医学与防护杂志,2005,25(6):586～588
14 Cella D,Dobrez D,Giaspy J.Control of cancer related anemia with erythropoietin agents:a review of evidence for improved quality of life and clinical outcomes.Ann Oncol,2003,14(4):511～519
15 Caro JJ,Salas M,Ward A,etal.Anemia as an independent prognostic factor for surviva in patients with cancer:a systemat ic,quantitative review.Cancer,2001,91(12):2214～2221
16 Cohen HJ . Geriatric principles of treatment applied to medical oncology . anoverview.Semin Oncol,1995,22(suppl 1):1～2
17 Vose JM.Cytokineuse in the older patient.Semin Oncol,1995,22(suppl 1):6～8
18 Cella D.Factors influencing quality of life in cancer patients Anemia and fatigue.Semin Oncol,1988,2s:43～46
19 Loretta MItri.Ortimal Hemoglobin level for cancer patients.semin oncol,2000,27(supple 4):12～15
20 Winninghan ML,Nail LM,Burke MB,et al.Fatigue and the cancer experience the state of the knowledge.Oncol Nurs Forum,1994,21:23～36
21 Cilla D.The Functional Assessment of Cancer Therapy-Anemia(FACT-AN)Scale a new tool for the assessment of outcomes in cancer anemia and fatigue.Semin Hematol,1997,34(suppl 2):13～19
22 Leitgeb C,Pecherstorfer M,Fritz E,et al.Quality of life in chronic anemia of cancer during treatment with rhEPO.Cancer,1994,73:2535～2542
23 Krishnasamy M.Social support and the patient with cancer:a consideration of the literature .Adv Nurs,1999,23(4):757～762
24 Liang BC.Effects of hypoxia on drug resiatance phenotype and genotype in human gliomacell lines.J NeuroOncol,1996,29(1):149～155
25 Denko NC,Giaccia AJ.Tumor hypoxia,the physiological link between Trousseaus syndrome(carcinoma induced coagulopathy)and metastasis.Cancer Res,2001,61(3):795～798
26 Krakt A,WwindelK,Ochs A,etal.Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.Cancer,1999,85:178～187
27 Miyake H,Hera I,Yamana k,etal.Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer.Urology,1999,53:302～307
28 Levy AP,Levy NS,Goldberg MA.Post transcriptional regulation of vasvular endothelial growth factor by hypoxia.J Biol Chem,1996,271:2746～2753
29 Albain KS,Crowley JJ,Leblanc M,et al.Survival determinants in extensive-stage NSCLC.J Clin Oncology,1991,9:1618～1626
30 徐朝久,张灿珍,丁纯志,等.治疗前血红蛋白水平评估小细胞肺癌预后意义.肿瘤学杂志,2004,10(4):243～245
31 王卫东,孙苏平,王向东.血红蛋白浓度对非小细胞肺癌放疗疗效的影响.肿瘤研究与临床,2004,16(4):239～241
32 Grogan M,Thomas GM,Melamed I,etal.The importance of hemoglobin levels duringradiotherapy for carcinoma of the cervix.Cancer,1999,86(8):1528～1536
33 Thomas G.The effect of hemoglobin level on radiotherapy ourcomes:the Canadian experience.Semin Oncol.2001.28(2 Suppl 8):60～65
34 Frommhold H,Gurrenberger R,Henke M.The impact of blood hemoglobin content on the outcomes of radiotherapy.Strahlenther Onkol,1998,174(Supp l4):31～34
35 Fein DA,Lee WR,Hanlon AL,etal.Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx.J Clin Oncol,1995,13(9):2077～2083
36 袁君,姜武忠,章正,等.血红蛋白浓度对鼻咽癌患者放射治疗远期疗效的影响.中国现代医学杂志,2003,13(10):103～104
37 Obermair A,Handisurya A,Kaider A,etal.The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients.Cancer,1998,83(4):726～731
38 侯家玉.中药药理学.北京:中国中医药出版社,2002,8
39 刘杰麟,章灵华,钱玉昆.枸杞多糖对S180荷瘤小鼠的免疫抑瘤作用.中国免疫学杂志,1996,12(2):115
40 杜守英.枸杞子水提取物对白介素6和肿瘤坏死因子产生的影响.中国免疫学杂志,1994,10(6):356
41 Toomey D , Redmond HP , Bouchier-Hayes D . Mechanisms mediating cancer cachexia.Cancer,1995,76(12):2418
42 李同度.临床肿瘤学.合肥:安徽科学技术出版社,1995,460
43 朱步东,刘淑俊,李淑芳.恶性肿瘤病人营养不良评价方法的比较.中国临床营养杂志,2000,8(1):39～40
44 王兵.癌舒康胶囊治疗癌症恶病质的实验研究.中国中医药信息杂志,2004,11(3),214～216
45 蔡红兵,罗荣城,杨传标,等.补中益气汤治疗癌症食欲不振-恶病质综合征 30 例疗效观察.新中医,2003,35(3):25～26
46 金嫣莉.十全大补汤与红参对妇科癌症患者恶液质倾向的改善作用.国外医学中医中药分册,1995,17(6):27
1 Jerome EG,Loretta MI.Chemotherapy-Induced Anemia in Adults.Incidence and Treatment.J Natl Cancer Inst,1999,91:1616～1634
2 Ludwig H,Fritz E.Anemia in cancer patients.Senin oncol,1998,25(supple 7):2～6
3 Gunter Weiss.Iron and anemia of chronic disease.Kidney International,1999,55:s12～s17
4 Wians FH Jr,Urban JE,Keffer JH,et al.Discriminating between iron deficiency anemia and anemia of chronic disease using traditional indices of iron status vs transferring receptor concentration.Am J Clin Pathol,2001,115:112～118
5 Fitzsimons EJ,Houston T,Munro R,et al.Erythroblast iron metabolism and serum soluble transferrin receptor values in the anemia of rheumatoid arthritis.Arthritis Rheum,2002,47:166～171
6 Okamoto H,Saijo N,Shinkai T,et al.Chemotherapy-induced anemia in patients with primary lung cancer.Ann oncol,1992,3:819～824
7 韦保和,莫志恒,成积儒.放射治疗对食管癌患者外周血象的影响.肿瘤防治研究,2000,27(4):280
8 Elis PA,Smith IE,Hardy JR,et al.Symptom relief with MVP(mitomycin c,vinblastine and cisplatin)chemotherapy in advanced NSCLC.Br J Cancer,1995,71:366～370
9 韩瑞刚,彭瑞云.电离辐射对骨髓损伤的研究进展.中华放射医学与防护杂志,2005,25(6):586～588
10 许昌韶,俞志英,姚德元,等.放射治疗对肿瘤患者血清运铁蛋白的影响.苏州医学院学报,1995,15(2):249～250
11 HDesrame JH,HBroustet HH,HDarodes de Tailly PH,et al.Oxaliplatin-induced haemolytic anaemia.HLancetH,1999,354(9185):1179～1180
12 HWalker RWH,HRosenblum MKH,HKempin SJH,et al.Carboplatin-associated thrombotic microangiopathic hemolytic anemia.HCancerH,1989,64(5):1017～1020
13 达万明,黄文荣.病毒感染与再生障碍性贫血.中国实用内科杂志,2002,22(3):133～135
14 Dilloo D,Vohringer R,Josting A,et al.Bone marrow fibroblasts from children with aplastic anemia exhibit reduced interlukin-6 production in response to cytokines and viral challenge.Pediatr Res,1995,38(5):716～721
15 Hoffman R.Hematology-Basic principles and practice.ed3.北京:科学技术出版社,2001,2410～2419
16 MoliternoAR,Spivak JK.Anemia of cancer.Hematol Oncol Clin NAm,1996,10(2):345
17 Rytting M,Worth L,Jaffe N.Hemolytic disorders associated with cancer.Hematol Oncol Clin North Am,1996,10:365
18 徐世荣.自身免疫性溶血性贫血.中国实用内科杂志,1996,10(9):511
19 沈迪,王辩明,余善俊,等.临床血液学.北京:人民卫生出版社,1989,397～399
20 汤钊猷.现代肿瘤学.第 2 版.上海:上海医科大学出版社,2000,599
21 Goad KE,Gralnick HR.Coagulation disorders in cancer.Hematol Oncol Clin North Am,1996,10:457
22 Lazzarino M,Morra E,Castello A,et al.Myelofibrosis in chronic granulocytic leukaemia:clinicopathologic correlations and prognostic significance.Br J Haematol,1986,64(2):227～240
23 Imbert M,Nguyen D,Sultan C.Myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) with myelofibrosis.Leuk Res,1992,16(1):51～54
24 Devred C,Diebold J.Myelofibrosis during hematologic disease.A propos of 402 cases.Sem Hop,1974,50:1625～1634
25 McCarthy DM.Annotation.Fibrosis of the bone marrow:content and causes.Br J Haematol,1985,59:1～7
26 Yokovama K,Amamiya T,KawaiY,et al.Acute lymphocytic leukemia associated with scvere myelofibrosis.Keio J Med,1997,46(4):196～204
27 Terra L,Reeder,Richard J,et al.Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia.Blood,2003,101(5):1981～1983
28 Nieto LH,Raya Sanchez JM,Arguelles HA,et al.A case of chronic lymphocytic leukemia overwhelmed by rapidly progression idiopathic myelofibrosis.Haemato- logica,2000,85:973～977
29 Shpall EJ,Gee AP,Hogan C,et al.Bone marrow metastases.Hematol Oncol Clin North Am,1996,10:321
30 叶絮,谭获,冯莹,等.慢性病贫血患者血清促红细胞生成素水平变化及其意义.广东医学,2004,25(1):49～50
31 Wood PA,Hrushesky WJM.Cisplatin associated anemia:an erythropoietin deficiency syndrome.J Clin Ivest,1995,95:1650～1659
32 Faquin WC,Schneider TJ,Goldberg MA.Effect of inflammatory cytokines on hypoxia-induced erythropoietin production.Blood,1997,79:1987～1994
33 Lawrence B,Gardener and Edward,Benz J.Anemia of chronic disease.血液病学基本原理与实践(英文影印版).北京:科学出版社,2000,383～387
34 Leng HMJ,Albrecht CF,Kidson SH,et al.Erythropoietin production in anemia associated with experimental cancer.Exp Hematol,1999,27:806～810
35 Dowlati A,R’Zik S,Fillet G,et al.Anaemia of lung cancer is due to impaired erythroid marrow response to erythropoietin stimulation as well as relative inadequacy of erythropoietin production.Br J Haematol,1997,97:297～299
36 Rusten LS,Jacobsen SEW.Tumor necrosis factor(TNF-α) directly inhibits human erythropoiesis in vitro:role of p55 and p75 TNF receptors.Blood,1995,85:989～996
37 Dai CH,Price JO,Brunner T,et al.Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon to produce erythroid cell apoptosis.Blood,1998,91:1235～1242
38 Nowrousian MR,Kasper C,Oberhoff C,et al.Pathophysiology of cancer-related anemia,in Smyth JF,Boogaerts MA,Ehmer BR-M(Eeds):rhEPO in Cancer Supporrtive Treatment.New Yard,NY,Marcel Dekker,1996,13～34
39 Feelders RA,Vreugdenhil G,Eggermont AM,et al.Regulation of iron metabolism in the acute phase response : interferon gamma and tumor necrosis factor alpha induce hypoferraemia,ferritin production and a decrease in circulating transferrin receptors in cancer patients.Eur J Clin Invest,1998,28:520～527
40 Fitzsimons EJ,Houston T,Munro R,et al.Erythroblast iron metabolism and serum soluble transferring receptor values in the anemia of rheumatoid arthritis.Arthritis Rheum,2002,47:166～171
41 Rogers J,Lacroix L,Durmowitz G,et al.The role of cytokines in the regulation of ferritin expression.Adv Exp Med Biol,1994,356:127～132
42 Abramson SD,Abramson N.‘Common’uncommon anemias.Am Fam Physician,1999,59:851～858
43 Mulero V,Brock JH.Regulation of iron metabolism in murine J744 macrophages:role of nitricoxide dependent and independent pathways following activation with gama interferon and lipopolysaceharide.Blood,1999,94:2383
44 Kim S,Ponka P.Effects of interferon gama and lipopolysaceharide on macrophage iron metabolism aremediated by nitricoxide induced degradation of iron regulatory protein2.J Biol Chem,2000,275:6220
45 Powers JS,Krantz SB,Collins JC,et al.Erythropoietin response to anemia as a function of age.J Am Geriatr Soc,1991,39:30
46 翟晓文,吴玥,顾小锋,等.慢性病贫血患儿肿瘤坏死因子α、白介素 6 与红细胞生成素的关系.中华儿科杂志,2004,42(1):62～65
47 Voulgari PV,Kolies G,Papadopoules GK,et al.Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritia.Clin Immunol,1999,92(2):153
48 孙卫民,王惠琴.细胞因子研究方法学(M).北京:人民卫生出版社,1999,7
49 Takei S,Redford A,Kalayama S,et al.Destabilization of tumor necrosis factor-alpha mRNA by 5-apha dihydrotestosterone in Jurkal cells.Life Sci,2000,66(20):277～282
50 肖卫国,欧凤荣,张丽君,等.肿瘤坏死因子α对红系祖细胞造血影响的实验研究。中华血液学杂志,2003,24(8),438～439
51 Cazzola M.Mechanism of anemia in patients with malignancy implication for the clinical use of recombinant human erythropoietin.Med Oncol,2000,17:11
52 Oldenburg B,Rouingsberger JC,Van Berge Henegouwen GP,et al.Iron and inflammatory bowel disease.Aliment Pharmacol Ther,2001,15:429
53 Taniguchi S,Dai CH,Price JO,et al.Interferonγdownregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-Ⅰreceptors in human erythroid colony-forming cells.Blood,1997,90(6):2244
54 Rokicka Piotrowicz M,Paszkowska M,Krol M,et al.Analysis of causes for anemia in patients with multiple myeloma.Pol Arch Med We Wn,2000,104:843～851
55 Measns RTJr.Advances in the anemia of chronic disease.Int J Hematol,1999,70:7～12
56 Measns RTJr,Dessypris EN,Krantz SB,et al.Inhibition of human erythriod colony forming units by interleukin1 is mediated by gamma interferon.J Cell Physiol,1992,150:59～64
1 Kasper C,Terhaar A,Fossa A,et al.Recombinant human erythropoietin in the treatment of cancer-related anaemia.Eur J Haematol,1997,58:251～256
2 Littlewood TJ,Bajotta E,Nortier JW,et al.Effects of epoetinaifa on hematologic parameters and quality of life in paitients receiving nonplatinum chemotherapy:results of a randomized,double blind,placebo controlled trial.J Clin Oncol,2001,19:2865～2874
3 Weiss MJ.New insights into erythropoietin ande poetinalfa:mechanisms of action,target tissues,and clinical applications.Oncologist,2003,8(Suppl3):18～29
4 Miller CB,Jones RJ, Piantadosi S,et al.Decreased erythropoietic response in patients with anemia of cancer.New Engl J Med,1990,322:1689～1695
5 Wood PA,Hrushesky WJM.Cisplatin associated anemia:an erythropoientin deficiency syndrome.J Clin Invest,1995,95:1650～1659
6 Okamoto H,Saijo N,Shinkai T,et al.Chemotherapy-induced anemia in patients with primary lung cancer.Ann oncol,1992,3:819～824
7 Rosso R,del Mastro L,Venturini M,et al.Use of erythropoietin in oncology.Tumori,1997,83(Suppl 2):26～38
8 Ebert BL,Bunn HF.Regulation of the erythropoietin gene.Blood,1999,94:1864～1877
9 Aoki I,Higashi K,Homori M,et al.Responsiveness of bone marrow erythropoietic stem cells(CFU-E and BFU-E)to recombinant human erythropoietin in vitro in aplastic anemia and myelodysplastic syndrome.Am J Hematol,1990,35:6
10 Means TR,Krantz SB.Inhibition of human erythriod colony forming units by interferon can be corrected by recombinant human erythropoietin.Blood,1991,78:2564～2673
11 刘宇飞,孙蔚莉,成卫.重组人红细胞生成素治疗恶性肿瘤化疗相关贫血的临床观察.江苏医药,2004,30(1):72
12 储大同,张湘茹,李丽庆,等.重组人红细胞生成素治疗肿瘤化疗相关贫血的作用.中华医学杂志,2001,81(17):1086～1087
13 Henry DH,Thatcher N.Patient selection and predicting response to recombinant human erythropoitin inanemic cancer patients.Semin Hematol,1996,33(Suppl 1):2～5
14 Ludwig H,Fritz E.Anemia of cancer patients:patient selection and patient stratification for epoetin treatment.Semin Oncol,1998,25(Suppl 7):35～38
15 Claspy J.The impact of poetinalfa on quality of life during cancer chemotherapy:afresh look at an old problem.Semin Hematol,1997,34(suppl 2):20～26
16 刘莉,丁乾,陆海,等.重组人红细胞生成素治疗晚期非小细胞肺癌化疗相关贫血疗效的观察.华中科技大学学报(医学版),2004,33(2):219～221
17 李勇,龙跃平.重组人促红细胞生成素治疗消化道恶性肿瘤伴贫血的临床研究.腹部外科,2002,15(4):236～237
18 李斌,陈晓钟,张鸿未,等.促红细胞生成素对放疗患者贫血的疗效.浙江中西医结合杂志,2004,14(7):407～408
19 Sweeney Pi,Nicolae D,Ignacio L,et al.Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy final report of a randomized,open-labelled,phase II trial.Br J Cancer,1998,77(11):1996～2002
20 Henke M,Guttenberger R,Barke A,et al.Erythropoietin for patients undergoing radiotherapy:apilot study.Radiother Oncol,1999,50(2):185～190
21 Antonadou D,Cardamakis E,Sarris G,et al.Effect of the administration of reombinant human erythropoietin in patients with pelvic malignancies during radiotherapy.Radiother Oncol,1998,48:483
22 Rose E,Rai K,Revicki D.Clinical and health status assessments in anemic chronic lymphocytic leukemia(CLL)patients treated with epoetin alfa.Blood,1994,8E(suppl 1):256
23 UrabeA.Phase study of recombinant human erythropoietin for anemia associated with multiple myeloma,A multcenter trial.Diagnosis Treatment,1993,81(9):1837～1854
24 Gabrilove JL,Einhorn LH,Livingston RB,et al.Once-Weekly dosing of epoetinalfa issimilar to three-times-weekly dosingin increasing haemoglobin and quality of life.Proc ASCO,1999,18:2216～2218
25 Littlewood TJ.Erythropoietin for the treatment of anemia associated with hematological malignancy.Hematol Oncol,2001,19:19～30
26 Gupta M,Goldwasser E.The role of the rear upstream sequence in hypoxia-in-duce dexpression of the erythropoietin gene.Nucleic Acids Research,1996,24:4768～4774
27 王文,张茂宏,徐从高.EPO 和铁代谢与恶性肿瘤贫血.中华血液学杂志,2001,22:222～223
28 邓家栋,杨崇礼,杨天楹.临床血液学.上海:科学技术出版社,2001,701～703
29 Beguin Y.Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.Med Oncol,1998,15(suppl 1):38～46
30 Abels RI,Larbolt KM,Krantz,et al.Recombinanthu-manreythropietin(HuEPO)for the treatment of the anemia of cancer;in Murphy MJJr (ed):blood cell growth factors:Their Present and future use in hematyology . Procceings of the Beijing Symposium.Dayton.Ohio,Al-pha Med Press,1991,121～141
31 Tsukuda M,Yuyama S,Kohnl H,et al.Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy induced anemia.Biotherapy,1998,11:21～25
32 Cella D,Bron D.The effect of Epoetinalfa on quality of life in anemic cancer patients.Cancer Pract,1999,7:177～182
33 Cella D,Dobrez D,Giaspy J.Control of cancer related anemia with erythropoietin agents:a review of evidence for improved quality of life and clinical outcomes.Ann Oncol,2003,14(4):511～519
34 Ozguroglu M,Arun B,Demir G,et al.Serum erythropoietin level in anemic cancer patients.Med Oncol,2000,17(1):29
35 Adamson JW,Ludwig H.Predicting the hematopoietic response to recombinant human erythropoietin(Epoetinalfa)in the treatment of the anemia of cancer.Oncology,1999,56:46～53
36 Cheung WK,Goon BL,Guilfoyle MC,et al.Pharmacokinetics and pharmacy dynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.Clin Pharmaclo Ther,1998,64(4):412
37 Ammarguellar F,Gofwsev J,Drueke TB.Direct effect of erythropoietin on rat vascular smooth-muscla cell via a pulative erythropoietin receptor.Netprol Dial Transplat,1996,11:687～692
38 Ozguroglu M,Arun B,Demir G,et al.Serum erythropoietin level in anemic cancerpatients.Med Oncol,2000,17:29～34
39 Johnson CS,Cook CA,Furmanski P.In vivo suppression of erythropoiesis by tumor necrosis factor-α:Reversal with exogenous erythropoietin(EPO).Exp Hematol,1990,18:109
40 Voulgari PV,Kolies G,Papadopoules GK,et al.Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritia.Clin Immunol,1999,92(2):153
41 钱家麒.重组人促红细胞生成素应用中的新问题—纯红再障.中国医学论坛报,2003,2(13):8
42 谷俊侠,陈燕,张纯.干细胞因子与促红细胞生成素联合应用对非霍奇金淋巴瘤贫血患者红系生成的作用.中国癌症杂志,2005,15(2)164～166
43 张红宇,孟庆祥,柳金,等.肿瘤性贫血病人血清促红细胞生成素和睾酮水平的研究.中国基层医药,2004,11(3),295～296
44 杨成民.基础输血学.北京:中国科学技术出版社,2001,349
45 张家华.现代血液病学.北京:人民军医出版社,1997,133～134
46 孟沛霖,阂碧荷.实用血液病手册.北京:人民军医出版社,2000,342
47 Wiesen AR,Hospenthal DR,Bm JC,et a1.Equilibration of hemoglobin concentration after transfusion in medical inpatients not a actively bleeding.Ann Intern Med,1994,121(3):278
48 Jensen LS,Hokland M,Nielsen HJ.A randomized controlled study of the effect of bedside lcucocyte depletion on the immunosuppressive effect of whole blood transfusion patients undergoing elective colorectal surgery.Br J Surg,1996,83(7):973～977
49 王承定,竺涵光,万光勇.术中输血对头颈部恶性肿瘤患者 T 淋巴细胞亚群的影响.口腔颌面外科杂志,1999,9(3):246~248
50 魏秀琴,苏雷,邓秀芝.围术期输血对肺癌病人T细胞亚群的影响.中国基层医药,2002,9(10):890～891
51 苏雷,魏秀芹,贤小丽,等.围术期输血与肺癌复发.现代诊断与治疗,2000,11(4):218～220
52 陈克能,师晓天,梅强,等.输血对食管癌病人免疫功能的影响.中华胸心血管外科杂志,2001,17(2):79～81
53 耿万明,苏跃,邝贤宣,等.输血对肺鳞癌患者红细胞免疫功能的影响.中国肺癌杂志,2000,3(3):218～219
54 张循善,李燕萍,张载福.食管癌患者围手术期同种输血后细胞因子和 NO 的变化及相互关系的探讨.中国病理生理杂志,2000,16(10):1069～1070
55 Christensen LI,Grunnet N,Rudiger N.Comparison of the level of cytokine mRNA in buffycoat derived platelet concentrates prepared with or without white cell reduction byfiltration.Transfusinon,1998,38(3):236～241
56 张献清,姚若全,穆士杰,等.输血对乳腺癌患者术后感染的影响观察.临床外科杂志,2002,10(6),348～349
57 徐银才,任俊泉,段元慧,等.输血对乳腺癌患者术后感染发生的影响.实用癌症杂志,2003,18(3):298
58 Jensen LS,Andersen AJ,Fristrup SG,et al.Post operative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery.Br J Surg,1992,79(6):513
59 Blajchman MA.Allogeneic blood transfusions,immunomodulation,and postoperative bacterial infection:do we have the answers yet?Transfusion,1997,37(2):121
60 Grogan M,Thomas GM,Melamed,ea tl.The important hemoglobin levels during radiotherapy for carcinoma of the cervix.Cancer,2001,86:1528
61 Vamvaks EC.Transfusion-associated cancer recurrence and postoperative infection:meta analysis of randomized,controlled clinical trials.Transfusion,1996,36:175～186
62 Waymack JP,Fernandes G,Yurt RW,et al.Effect of blood transfusion on immune function.Part Ⅵ.Effect on immunologic response to tumor.Surgry,1990,108(2):172～177
63 Edna TH,Bjerkeset T.Perioperative blood transfusions reduce long term survival following surgery for colorectal cancer.Dis Colon Rectum,1998,41:451～459
64 Heiss MM,Mempel W,Delanoff C,et al.Blood transfusion modulated tumor recurrence:first results of a randomized study of autologus versus allogenic blood transfusion in colorectal cancer surgery.J Chin Oncol,1994,12(9):1280～1281
65 Fung Y,Karpeh M,mager K.Assoiciation of perioperative transfusion with poor outcome in resection of gastricadenocacinoma.Am J surg,1994,167(2):256～260
66 焦顺昌,张文芹,杨俊兰,等.围手术期输血对非小细胞肺癌患者术后无病生存的影响.第四军医大学学报,2004,25(11):1035～1038
67 程邦昌,陈克能,梅强,等.食管癌患者外周血 T 淋巴细胞亚群、TNF 的变化及其影响因素.中华实验外科杂志,1998,15:228
68 侯建民,陈克能,王社军.全麻对食管癌患者细胞免疫功能的影响.中华麻醉杂志,1998,18:283
69 许利民,洪淋,张书模.低温冷冻后红细胞免疫功能的变化及意义.中国免疫学杂志,1995,11:239
70 单丽娟.血液病血虚从脾论治初探.新疆中医药,1996,(3):1838
71 江克明.补血八法.开卷有益·求医问药,2002,(6):16
72 孙伟芬.紫参汤治疗癌性贫血 47 例疗效观察.福建中医药,2000,1:36～39
73 张静.中药对癌症患者恶病质状态的影响.中国中西医结合杂志,2000,20(11):871
74 刘永花,卢绪叶.参麦注射液治疗肿瘤化疗后骨髓抑制临床观察.四川中医,2001,19(5):44～46
75 焦立新,李艳萍.参附注射液治疗肿瘤化疗后骨髓抑制的疗效观察.辽宁中医杂志,2002,29(2):89
76 Nowrousian MR.Recombinant human erythropoietin in the treatment of cancer related or chemotherapy induced anaemia in patients with solid tumors.Med Oncol,1998,15(Suppl 1):19～28
77 徐月明,叶中景,蒋旭金.恶性肿瘤化疗出现肾功能损害的治疗分析.中国现代医学杂志,1999,9(6):19～20
2 Jerome EG,Loretta MI.Chemotherapy-Induced Anemia in Adults.Incidence and Treatment.J Natl Cancer Inst,1999,91:1616～1634
3 Skiuings JR,Rogers-Melamed I,Nabholtz JM,et al.An epidemiological review of anemia in cancer chemotherapy in Cannada,proceedings of the European Conference on clinicaloncology and Cancer Nursing European Society of Therapeutic Radiology and Oncology.Paris France,October 29～November 2,1995:183
4 宋国红,刘淑俊,聂均,等.肿瘤伴发贫血及其对肿瘤患者生活质量影响的调查.肿瘤防治杂志,2003,10(11):1186～1188
5 Reed WR,Hussey DH,De Gowin RL.Implications of the anemia of chronic disorders in patients anticipating radiotherapy.Am J Med sci,1994,308:9～15
6 Okamoto H,Saijo N,Shinkai T,et al.Chemotherapy-induced anemia in patients with primary lung cancer.Ann oncol,1992,3:819～824
7 Wozniak AJ,Crowley JJ,Balcerxak SP,et al.Randomized trail comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced NSCLC:a southwest Oncology Group study.J clin oncol,1998,16:2459～2465
8 Elis PA,Smith IE,Hardy JR,et al.Symptom relief with MVP(mitomycin c,vinblastine and cisplatin)chemotherapy in advanced NSCLC.Br J Cancer,1995,71:366～370
9 Post mus PE,Giaccone G,Debruyne C,et al.Results of the phase ⅠEORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with NSCLC.EORTC lung cancer cooperating group,Semin Oncol,1996,23(supple 12):10～13
10 Hainsworth JD,Levitan N,Wampler GL,et al.phase Ⅰ randomized study of cisplatin plus etoposide phosphate or etoposidein the treatment of small-cell lung cancer(SCLC).J clin oncol,1995,13:1436～1442
11 Loehter PJ SR,Ansari R,Gonin R,et al.Cisplatin plus etoposide with and without ifosfamide in extensive SCLC a Hoosier oncology groop study.J clin oncol,1995,13:1594～1599
12 Miuer AA,Hermdon JE znd,Houis DR,et al.Schedule dependency of 21-day oral versus 3-day intravenous etopside in combinatoion with intravenous cisplatin in extensiveSCLC:a randomized phase Ⅰ study of the cancer of leukemia group B.J clin oncol,1995,13:1871～1879
13 韩瑞刚,彭瑞云.电离辐射对骨髓损伤的研究进展.中华放射医学与防护杂志,2005,25(6):586～588
14 Cella D,Dobrez D,Giaspy J.Control of cancer related anemia with erythropoietin agents:a review of evidence for improved quality of life and clinical outcomes.Ann Oncol,2003,14(4):511～519
15 Caro JJ,Salas M,Ward A,etal.Anemia as an independent prognostic factor for surviva in patients with cancer:a systemat ic,quantitative review.Cancer,2001,91(12):2214～2221
16 Cohen HJ . Geriatric principles of treatment applied to medical oncology . anoverview.Semin Oncol,1995,22(suppl 1):1～2
17 Vose JM.Cytokineuse in the older patient.Semin Oncol,1995,22(suppl 1):6～8
18 Cella D.Factors influencing quality of life in cancer patients Anemia and fatigue.Semin Oncol,1988,2s:43～46
19 Loretta MItri.Ortimal Hemoglobin level for cancer patients.semin oncol,2000,27(supple 4):12～15
20 Winninghan ML,Nail LM,Burke MB,et al.Fatigue and the cancer experience the state of the knowledge.Oncol Nurs Forum,1994,21:23～36
21 Cilla D.The Functional Assessment of Cancer Therapy-Anemia(FACT-AN)Scale a new tool for the assessment of outcomes in cancer anemia and fatigue.Semin Hematol,1997,34(suppl 2):13～19
22 Leitgeb C,Pecherstorfer M,Fritz E,et al.Quality of life in chronic anemia of cancer during treatment with rhEPO.Cancer,1994,73:2535～2542
23 Krishnasamy M.Social support and the patient with cancer:a consideration of the literature .Adv Nurs,1999,23(4):757～762
24 Liang BC.Effects of hypoxia on drug resiatance phenotype and genotype in human gliomacell lines.J NeuroOncol,1996,29(1):149～155
25 Denko NC,Giaccia AJ.Tumor hypoxia,the physiological link between Trousseaus syndrome(carcinoma induced coagulopathy)and metastasis.Cancer Res,2001,61(3):795～798
26 Krakt A,WwindelK,Ochs A,etal.Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.Cancer,1999,85:178～187
27 Miyake H,Hera I,Yamana k,etal.Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer.Urology,1999,53:302～307
28 Levy AP,Levy NS,Goldberg MA.Post transcriptional regulation of vasvular endothelial growth factor by hypoxia.J Biol Chem,1996,271:2746～2753
29 Albain KS,Crowley JJ,Leblanc M,et al.Survival determinants in extensive-stage NSCLC.J Clin Oncology,1991,9:1618～1626
30 徐朝久,张灿珍,丁纯志,等.治疗前血红蛋白水平评估小细胞肺癌预后意义.肿瘤学杂志,2004,10(4):243～245
31 王卫东,孙苏平,王向东.血红蛋白浓度对非小细胞肺癌放疗疗效的影响.肿瘤研究与临床,2004,16(4):239～241
32 Grogan M,Thomas GM,Melamed I,etal.The importance of hemoglobin levels duringradiotherapy for carcinoma of the cervix.Cancer,1999,86(8):1528～1536
33 Thomas G.The effect of hemoglobin level on radiotherapy ourcomes:the Canadian experience.Semin Oncol.2001.28(2 Suppl 8):60～65
34 Frommhold H,Gurrenberger R,Henke M.The impact of blood hemoglobin content on the outcomes of radiotherapy.Strahlenther Onkol,1998,174(Supp l4):31～34
35 Fein DA,Lee WR,Hanlon AL,etal.Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx.J Clin Oncol,1995,13(9):2077～2083
36 袁君,姜武忠,章正,等.血红蛋白浓度对鼻咽癌患者放射治疗远期疗效的影响.中国现代医学杂志,2003,13(10):103～104
37 Obermair A,Handisurya A,Kaider A,etal.The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients.Cancer,1998,83(4):726～731
38 侯家玉.中药药理学.北京:中国中医药出版社,2002,8
39 刘杰麟,章灵华,钱玉昆.枸杞多糖对S180荷瘤小鼠的免疫抑瘤作用.中国免疫学杂志,1996,12(2):115
40 杜守英.枸杞子水提取物对白介素6和肿瘤坏死因子产生的影响.中国免疫学杂志,1994,10(6):356
41 Toomey D , Redmond HP , Bouchier-Hayes D . Mechanisms mediating cancer cachexia.Cancer,1995,76(12):2418
42 李同度.临床肿瘤学.合肥:安徽科学技术出版社,1995,460
43 朱步东,刘淑俊,李淑芳.恶性肿瘤病人营养不良评价方法的比较.中国临床营养杂志,2000,8(1):39～40
44 王兵.癌舒康胶囊治疗癌症恶病质的实验研究.中国中医药信息杂志,2004,11(3),214～216
45 蔡红兵,罗荣城,杨传标,等.补中益气汤治疗癌症食欲不振-恶病质综合征 30 例疗效观察.新中医,2003,35(3):25～26
46 金嫣莉.十全大补汤与红参对妇科癌症患者恶液质倾向的改善作用.国外医学中医中药分册,1995,17(6):27
1 Jerome EG,Loretta MI.Chemotherapy-Induced Anemia in Adults.Incidence and Treatment.J Natl Cancer Inst,1999,91:1616～1634
2 Ludwig H,Fritz E.Anemia in cancer patients.Senin oncol,1998,25(supple 7):2～6
3 Gunter Weiss.Iron and anemia of chronic disease.Kidney International,1999,55:s12～s17
4 Wians FH Jr,Urban JE,Keffer JH,et al.Discriminating between iron deficiency anemia and anemia of chronic disease using traditional indices of iron status vs transferring receptor concentration.Am J Clin Pathol,2001,115:112～118
5 Fitzsimons EJ,Houston T,Munro R,et al.Erythroblast iron metabolism and serum soluble transferrin receptor values in the anemia of rheumatoid arthritis.Arthritis Rheum,2002,47:166～171
6 Okamoto H,Saijo N,Shinkai T,et al.Chemotherapy-induced anemia in patients with primary lung cancer.Ann oncol,1992,3:819～824
7 韦保和,莫志恒,成积儒.放射治疗对食管癌患者外周血象的影响.肿瘤防治研究,2000,27(4):280
8 Elis PA,Smith IE,Hardy JR,et al.Symptom relief with MVP(mitomycin c,vinblastine and cisplatin)chemotherapy in advanced NSCLC.Br J Cancer,1995,71:366～370
9 韩瑞刚,彭瑞云.电离辐射对骨髓损伤的研究进展.中华放射医学与防护杂志,2005,25(6):586～588
10 许昌韶,俞志英,姚德元,等.放射治疗对肿瘤患者血清运铁蛋白的影响.苏州医学院学报,1995,15(2):249～250
11 HDesrame JH,HBroustet HH,HDarodes de Tailly PH,et al.Oxaliplatin-induced haemolytic anaemia.HLancetH,1999,354(9185):1179～1180
12 HWalker RWH,HRosenblum MKH,HKempin SJH,et al.Carboplatin-associated thrombotic microangiopathic hemolytic anemia.HCancerH,1989,64(5):1017～1020
13 达万明,黄文荣.病毒感染与再生障碍性贫血.中国实用内科杂志,2002,22(3):133～135
14 Dilloo D,Vohringer R,Josting A,et al.Bone marrow fibroblasts from children with aplastic anemia exhibit reduced interlukin-6 production in response to cytokines and viral challenge.Pediatr Res,1995,38(5):716～721
15 Hoffman R.Hematology-Basic principles and practice.ed3.北京:科学技术出版社,2001,2410～2419
16 MoliternoAR,Spivak JK.Anemia of cancer.Hematol Oncol Clin NAm,1996,10(2):345
17 Rytting M,Worth L,Jaffe N.Hemolytic disorders associated with cancer.Hematol Oncol Clin North Am,1996,10:365
18 徐世荣.自身免疫性溶血性贫血.中国实用内科杂志,1996,10(9):511
19 沈迪,王辩明,余善俊,等.临床血液学.北京:人民卫生出版社,1989,397～399
20 汤钊猷.现代肿瘤学.第 2 版.上海:上海医科大学出版社,2000,599
21 Goad KE,Gralnick HR.Coagulation disorders in cancer.Hematol Oncol Clin North Am,1996,10:457
22 Lazzarino M,Morra E,Castello A,et al.Myelofibrosis in chronic granulocytic leukaemia:clinicopathologic correlations and prognostic significance.Br J Haematol,1986,64(2):227～240
23 Imbert M,Nguyen D,Sultan C.Myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) with myelofibrosis.Leuk Res,1992,16(1):51～54
24 Devred C,Diebold J.Myelofibrosis during hematologic disease.A propos of 402 cases.Sem Hop,1974,50:1625～1634
25 McCarthy DM.Annotation.Fibrosis of the bone marrow:content and causes.Br J Haematol,1985,59:1～7
26 Yokovama K,Amamiya T,KawaiY,et al.Acute lymphocytic leukemia associated with scvere myelofibrosis.Keio J Med,1997,46(4):196～204
27 Terra L,Reeder,Richard J,et al.Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia.Blood,2003,101(5):1981～1983
28 Nieto LH,Raya Sanchez JM,Arguelles HA,et al.A case of chronic lymphocytic leukemia overwhelmed by rapidly progression idiopathic myelofibrosis.Haemato- logica,2000,85:973～977
29 Shpall EJ,Gee AP,Hogan C,et al.Bone marrow metastases.Hematol Oncol Clin North Am,1996,10:321
30 叶絮,谭获,冯莹,等.慢性病贫血患者血清促红细胞生成素水平变化及其意义.广东医学,2004,25(1):49～50
31 Wood PA,Hrushesky WJM.Cisplatin associated anemia:an erythropoietin deficiency syndrome.J Clin Ivest,1995,95:1650～1659
32 Faquin WC,Schneider TJ,Goldberg MA.Effect of inflammatory cytokines on hypoxia-induced erythropoietin production.Blood,1997,79:1987～1994
33 Lawrence B,Gardener and Edward,Benz J.Anemia of chronic disease.血液病学基本原理与实践(英文影印版).北京:科学出版社,2000,383～387
34 Leng HMJ,Albrecht CF,Kidson SH,et al.Erythropoietin production in anemia associated with experimental cancer.Exp Hematol,1999,27:806～810
35 Dowlati A,R’Zik S,Fillet G,et al.Anaemia of lung cancer is due to impaired erythroid marrow response to erythropoietin stimulation as well as relative inadequacy of erythropoietin production.Br J Haematol,1997,97:297～299
36 Rusten LS,Jacobsen SEW.Tumor necrosis factor(TNF-α) directly inhibits human erythropoiesis in vitro:role of p55 and p75 TNF receptors.Blood,1995,85:989～996
37 Dai CH,Price JO,Brunner T,et al.Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon to produce erythroid cell apoptosis.Blood,1998,91:1235～1242
38 Nowrousian MR,Kasper C,Oberhoff C,et al.Pathophysiology of cancer-related anemia,in Smyth JF,Boogaerts MA,Ehmer BR-M(Eeds):rhEPO in Cancer Supporrtive Treatment.New Yard,NY,Marcel Dekker,1996,13～34
39 Feelders RA,Vreugdenhil G,Eggermont AM,et al.Regulation of iron metabolism in the acute phase response : interferon gamma and tumor necrosis factor alpha induce hypoferraemia,ferritin production and a decrease in circulating transferrin receptors in cancer patients.Eur J Clin Invest,1998,28:520～527
40 Fitzsimons EJ,Houston T,Munro R,et al.Erythroblast iron metabolism and serum soluble transferring receptor values in the anemia of rheumatoid arthritis.Arthritis Rheum,2002,47:166～171
41 Rogers J,Lacroix L,Durmowitz G,et al.The role of cytokines in the regulation of ferritin expression.Adv Exp Med Biol,1994,356:127～132
42 Abramson SD,Abramson N.‘Common’uncommon anemias.Am Fam Physician,1999,59:851～858
43 Mulero V,Brock JH.Regulation of iron metabolism in murine J744 macrophages:role of nitricoxide dependent and independent pathways following activation with gama interferon and lipopolysaceharide.Blood,1999,94:2383
44 Kim S,Ponka P.Effects of interferon gama and lipopolysaceharide on macrophage iron metabolism aremediated by nitricoxide induced degradation of iron regulatory protein2.J Biol Chem,2000,275:6220
45 Powers JS,Krantz SB,Collins JC,et al.Erythropoietin response to anemia as a function of age.J Am Geriatr Soc,1991,39:30
46 翟晓文,吴玥,顾小锋,等.慢性病贫血患儿肿瘤坏死因子α、白介素 6 与红细胞生成素的关系.中华儿科杂志,2004,42(1):62～65
47 Voulgari PV,Kolies G,Papadopoules GK,et al.Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritia.Clin Immunol,1999,92(2):153
48 孙卫民,王惠琴.细胞因子研究方法学(M).北京:人民卫生出版社,1999,7
49 Takei S,Redford A,Kalayama S,et al.Destabilization of tumor necrosis factor-alpha mRNA by 5-apha dihydrotestosterone in Jurkal cells.Life Sci,2000,66(20):277～282
50 肖卫国,欧凤荣,张丽君,等.肿瘤坏死因子α对红系祖细胞造血影响的实验研究。中华血液学杂志,2003,24(8),438～439
51 Cazzola M.Mechanism of anemia in patients with malignancy implication for the clinical use of recombinant human erythropoietin.Med Oncol,2000,17:11
52 Oldenburg B,Rouingsberger JC,Van Berge Henegouwen GP,et al.Iron and inflammatory bowel disease.Aliment Pharmacol Ther,2001,15:429
53 Taniguchi S,Dai CH,Price JO,et al.Interferonγdownregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-Ⅰreceptors in human erythroid colony-forming cells.Blood,1997,90(6):2244
54 Rokicka Piotrowicz M,Paszkowska M,Krol M,et al.Analysis of causes for anemia in patients with multiple myeloma.Pol Arch Med We Wn,2000,104:843～851
55 Measns RTJr.Advances in the anemia of chronic disease.Int J Hematol,1999,70:7～12
56 Measns RTJr,Dessypris EN,Krantz SB,et al.Inhibition of human erythriod colony forming units by interleukin1 is mediated by gamma interferon.J Cell Physiol,1992,150:59～64
1 Kasper C,Terhaar A,Fossa A,et al.Recombinant human erythropoietin in the treatment of cancer-related anaemia.Eur J Haematol,1997,58:251～256
2 Littlewood TJ,Bajotta E,Nortier JW,et al.Effects of epoetinaifa on hematologic parameters and quality of life in paitients receiving nonplatinum chemotherapy:results of a randomized,double blind,placebo controlled trial.J Clin Oncol,2001,19:2865～2874
3 Weiss MJ.New insights into erythropoietin ande poetinalfa:mechanisms of action,target tissues,and clinical applications.Oncologist,2003,8(Suppl3):18～29
4 Miller CB,Jones RJ, Piantadosi S,et al.Decreased erythropoietic response in patients with anemia of cancer.New Engl J Med,1990,322:1689～1695
5 Wood PA,Hrushesky WJM.Cisplatin associated anemia:an erythropoientin deficiency syndrome.J Clin Invest,1995,95:1650～1659
6 Okamoto H,Saijo N,Shinkai T,et al.Chemotherapy-induced anemia in patients with primary lung cancer.Ann oncol,1992,3:819～824
7 Rosso R,del Mastro L,Venturini M,et al.Use of erythropoietin in oncology.Tumori,1997,83(Suppl 2):26～38
8 Ebert BL,Bunn HF.Regulation of the erythropoietin gene.Blood,1999,94:1864～1877
9 Aoki I,Higashi K,Homori M,et al.Responsiveness of bone marrow erythropoietic stem cells(CFU-E and BFU-E)to recombinant human erythropoietin in vitro in aplastic anemia and myelodysplastic syndrome.Am J Hematol,1990,35:6
10 Means TR,Krantz SB.Inhibition of human erythriod colony forming units by interferon can be corrected by recombinant human erythropoietin.Blood,1991,78:2564～2673
11 刘宇飞,孙蔚莉,成卫.重组人红细胞生成素治疗恶性肿瘤化疗相关贫血的临床观察.江苏医药,2004,30(1):72
12 储大同,张湘茹,李丽庆,等.重组人红细胞生成素治疗肿瘤化疗相关贫血的作用.中华医学杂志,2001,81(17):1086～1087
13 Henry DH,Thatcher N.Patient selection and predicting response to recombinant human erythropoitin inanemic cancer patients.Semin Hematol,1996,33(Suppl 1):2～5
14 Ludwig H,Fritz E.Anemia of cancer patients:patient selection and patient stratification for epoetin treatment.Semin Oncol,1998,25(Suppl 7):35～38
15 Claspy J.The impact of poetinalfa on quality of life during cancer chemotherapy:afresh look at an old problem.Semin Hematol,1997,34(suppl 2):20～26
16 刘莉,丁乾,陆海,等.重组人红细胞生成素治疗晚期非小细胞肺癌化疗相关贫血疗效的观察.华中科技大学学报(医学版),2004,33(2):219～221
17 李勇,龙跃平.重组人促红细胞生成素治疗消化道恶性肿瘤伴贫血的临床研究.腹部外科,2002,15(4):236～237
18 李斌,陈晓钟,张鸿未,等.促红细胞生成素对放疗患者贫血的疗效.浙江中西医结合杂志,2004,14(7):407～408
19 Sweeney Pi,Nicolae D,Ignacio L,et al.Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy final report of a randomized,open-labelled,phase II trial.Br J Cancer,1998,77(11):1996～2002
20 Henke M,Guttenberger R,Barke A,et al.Erythropoietin for patients undergoing radiotherapy:apilot study.Radiother Oncol,1999,50(2):185～190
21 Antonadou D,Cardamakis E,Sarris G,et al.Effect of the administration of reombinant human erythropoietin in patients with pelvic malignancies during radiotherapy.Radiother Oncol,1998,48:483
22 Rose E,Rai K,Revicki D.Clinical and health status assessments in anemic chronic lymphocytic leukemia(CLL)patients treated with epoetin alfa.Blood,1994,8E(suppl 1):256
23 UrabeA.Phase study of recombinant human erythropoietin for anemia associated with multiple myeloma,A multcenter trial.Diagnosis Treatment,1993,81(9):1837～1854
24 Gabrilove JL,Einhorn LH,Livingston RB,et al.Once-Weekly dosing of epoetinalfa issimilar to three-times-weekly dosingin increasing haemoglobin and quality of life.Proc ASCO,1999,18:2216～2218
25 Littlewood TJ.Erythropoietin for the treatment of anemia associated with hematological malignancy.Hematol Oncol,2001,19:19～30
26 Gupta M,Goldwasser E.The role of the rear upstream sequence in hypoxia-in-duce dexpression of the erythropoietin gene.Nucleic Acids Research,1996,24:4768～4774
27 王文,张茂宏,徐从高.EPO 和铁代谢与恶性肿瘤贫血.中华血液学杂志,2001,22:222～223
28 邓家栋,杨崇礼,杨天楹.临床血液学.上海:科学技术出版社,2001,701～703
29 Beguin Y.Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.Med Oncol,1998,15(suppl 1):38～46
30 Abels RI,Larbolt KM,Krantz,et al.Recombinanthu-manreythropietin(HuEPO)for the treatment of the anemia of cancer;in Murphy MJJr (ed):blood cell growth factors:Their Present and future use in hematyology . Procceings of the Beijing Symposium.Dayton.Ohio,Al-pha Med Press,1991,121～141
31 Tsukuda M,Yuyama S,Kohnl H,et al.Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy induced anemia.Biotherapy,1998,11:21～25
32 Cella D,Bron D.The effect of Epoetinalfa on quality of life in anemic cancer patients.Cancer Pract,1999,7:177～182
33 Cella D,Dobrez D,Giaspy J.Control of cancer related anemia with erythropoietin agents:a review of evidence for improved quality of life and clinical outcomes.Ann Oncol,2003,14(4):511～519
34 Ozguroglu M,Arun B,Demir G,et al.Serum erythropoietin level in anemic cancer patients.Med Oncol,2000,17(1):29
35 Adamson JW,Ludwig H.Predicting the hematopoietic response to recombinant human erythropoietin(Epoetinalfa)in the treatment of the anemia of cancer.Oncology,1999,56:46～53
36 Cheung WK,Goon BL,Guilfoyle MC,et al.Pharmacokinetics and pharmacy dynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.Clin Pharmaclo Ther,1998,64(4):412
37 Ammarguellar F,Gofwsev J,Drueke TB.Direct effect of erythropoietin on rat vascular smooth-muscla cell via a pulative erythropoietin receptor.Netprol Dial Transplat,1996,11:687～692
38 Ozguroglu M,Arun B,Demir G,et al.Serum erythropoietin level in anemic cancerpatients.Med Oncol,2000,17:29～34
39 Johnson CS,Cook CA,Furmanski P.In vivo suppression of erythropoiesis by tumor necrosis factor-α:Reversal with exogenous erythropoietin(EPO).Exp Hematol,1990,18:109
40 Voulgari PV,Kolies G,Papadopoules GK,et al.Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritia.Clin Immunol,1999,92(2):153
41 钱家麒.重组人促红细胞生成素应用中的新问题—纯红再障.中国医学论坛报,2003,2(13):8
42 谷俊侠,陈燕,张纯.干细胞因子与促红细胞生成素联合应用对非霍奇金淋巴瘤贫血患者红系生成的作用.中国癌症杂志,2005,15(2)164～166
43 张红宇,孟庆祥,柳金,等.肿瘤性贫血病人血清促红细胞生成素和睾酮水平的研究.中国基层医药,2004,11(3),295～296
44 杨成民.基础输血学.北京:中国科学技术出版社,2001,349
45 张家华.现代血液病学.北京:人民军医出版社,1997,133～134
46 孟沛霖,阂碧荷.实用血液病手册.北京:人民军医出版社,2000,342
47 Wiesen AR,Hospenthal DR,Bm JC,et a1.Equilibration of hemoglobin concentration after transfusion in medical inpatients not a actively bleeding.Ann Intern Med,1994,121(3):278
48 Jensen LS,Hokland M,Nielsen HJ.A randomized controlled study of the effect of bedside lcucocyte depletion on the immunosuppressive effect of whole blood transfusion patients undergoing elective colorectal surgery.Br J Surg,1996,83(7):973～977
49 王承定,竺涵光,万光勇.术中输血对头颈部恶性肿瘤患者 T 淋巴细胞亚群的影响.口腔颌面外科杂志,1999,9(3):246~248
50 魏秀琴,苏雷,邓秀芝.围术期输血对肺癌病人T细胞亚群的影响.中国基层医药,2002,9(10):890～891
51 苏雷,魏秀芹,贤小丽,等.围术期输血与肺癌复发.现代诊断与治疗,2000,11(4):218～220
52 陈克能,师晓天,梅强,等.输血对食管癌病人免疫功能的影响.中华胸心血管外科杂志,2001,17(2):79～81
53 耿万明,苏跃,邝贤宣,等.输血对肺鳞癌患者红细胞免疫功能的影响.中国肺癌杂志,2000,3(3):218～219
54 张循善,李燕萍,张载福.食管癌患者围手术期同种输血后细胞因子和 NO 的变化及相互关系的探讨.中国病理生理杂志,2000,16(10):1069～1070
55 Christensen LI,Grunnet N,Rudiger N.Comparison of the level of cytokine mRNA in buffycoat derived platelet concentrates prepared with or without white cell reduction byfiltration.Transfusinon,1998,38(3):236～241
56 张献清,姚若全,穆士杰,等.输血对乳腺癌患者术后感染的影响观察.临床外科杂志,2002,10(6),348～349
57 徐银才,任俊泉,段元慧,等.输血对乳腺癌患者术后感染发生的影响.实用癌症杂志,2003,18(3):298
58 Jensen LS,Andersen AJ,Fristrup SG,et al.Post operative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery.Br J Surg,1992,79(6):513
59 Blajchman MA.Allogeneic blood transfusions,immunomodulation,and postoperative bacterial infection:do we have the answers yet?Transfusion,1997,37(2):121
60 Grogan M,Thomas GM,Melamed,ea tl.The important hemoglobin levels during radiotherapy for carcinoma of the cervix.Cancer,2001,86:1528
61 Vamvaks EC.Transfusion-associated cancer recurrence and postoperative infection:meta analysis of randomized,controlled clinical trials.Transfusion,1996,36:175～186
62 Waymack JP,Fernandes G,Yurt RW,et al.Effect of blood transfusion on immune function.Part Ⅵ.Effect on immunologic response to tumor.Surgry,1990,108(2):172～177
63 Edna TH,Bjerkeset T.Perioperative blood transfusions reduce long term survival following surgery for colorectal cancer.Dis Colon Rectum,1998,41:451～459
64 Heiss MM,Mempel W,Delanoff C,et al.Blood transfusion modulated tumor recurrence:first results of a randomized study of autologus versus allogenic blood transfusion in colorectal cancer surgery.J Chin Oncol,1994,12(9):1280～1281
65 Fung Y,Karpeh M,mager K.Assoiciation of perioperative transfusion with poor outcome in resection of gastricadenocacinoma.Am J surg,1994,167(2):256～260
66 焦顺昌,张文芹,杨俊兰,等.围手术期输血对非小细胞肺癌患者术后无病生存的影响.第四军医大学学报,2004,25(11):1035～1038
67 程邦昌,陈克能,梅强,等.食管癌患者外周血 T 淋巴细胞亚群、TNF 的变化及其影响因素.中华实验外科杂志,1998,15:228
68 侯建民,陈克能,王社军.全麻对食管癌患者细胞免疫功能的影响.中华麻醉杂志,1998,18:283
69 许利民,洪淋,张书模.低温冷冻后红细胞免疫功能的变化及意义.中国免疫学杂志,1995,11:239
70 单丽娟.血液病血虚从脾论治初探.新疆中医药,1996,(3):1838
71 江克明.补血八法.开卷有益·求医问药,2002,(6):16
72 孙伟芬.紫参汤治疗癌性贫血 47 例疗效观察.福建中医药,2000,1:36～39
73 张静.中药对癌症患者恶病质状态的影响.中国中西医结合杂志,2000,20(11):871
74 刘永花,卢绪叶.参麦注射液治疗肿瘤化疗后骨髓抑制临床观察.四川中医,2001,19(5):44～46
75 焦立新,李艳萍.参附注射液治疗肿瘤化疗后骨髓抑制的疗效观察.辽宁中医杂志,2002,29(2):89
76 Nowrousian MR.Recombinant human erythropoietin in the treatment of cancer related or chemotherapy induced anaemia in patients with solid tumors.Med Oncol,1998,15(Suppl 1):19～28
77 徐月明,叶中景,蒋旭金.恶性肿瘤化疗出现肾功能损害的治疗分析.中国现代医学杂志,1999,9(6):19～20